Tildrakizumab is an interleukin-23 antagonist approved under the brand name Ilumya for the treatment of plaque psoriasis.

Lower muscle volume, and more fat stored in the muscle, are seen linked to higher risk for disease and comorbidities.

UCB emerged as a major biopharmaceutical player in the 1990s with the development of blockbuster drugs Zyrtec and Keppra. Throughout the 1990s and early 2000s, UCB transformed from a hybrid ...

Researchers have found in a new research that deucravacitinib significantly improves joint pain and musculoskeletal symptoms ...

A new study from scientists at Scripps Research suggests that a drug already approved by the FDA to treat inflammation could help people with alcohol use disorder (AUD) by reducing both alcohol ...

Understand how psoriatic arthritis increases heart disease risk through inflammation. Learn management tips for heart health, from lifestyle changes to medication discussions.

Submission is supported by 24-week results from the Phase 3b APEX study in adults with active psoriatic arthritis treated ...

The FDA has accepted for review the sNDA for deucravacitinib for the treatment of adults with active psoriatic arthritis.

Tumor necrosis factor inhibitor use in patients with IMIDs did not increase the risk of de novo heart failure or worsen existing heart failure.

Medicare may cover Skyrizi (risankizumab-rzaa) if you have a plan with prescription drug benefits. Learn more.

Sun Pharma’s INSPIRE-1 and INSPIRE-2 studies met their primary endpoint at Week 24, with Ilumya 100 mg demonstrating superior ...